Lenalidomide Orion

Lenalidomide, the active ingredient in Lenalidomide Orion, is a immunomodulatory imide drug (IMiD) presented as an oral formulation for systemic use. It is indicated for certain blood cancers and is administered under medical supervision. GNH USA supplies Lenalidomide Orion as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, oncology centres, pharmacies and clinics worldwide.

Lenalidomide Orion is employed in hematologic malignancies that respond to immunomodulatory therapy. - Multiple Myeloma: improves progression‑free survival and overall response rates in patients with relapsed or refractory disease. - Myelodysplastic Syndromes with del(5q): reduces transfusion dependence and induces cytogenetic remission. - Mantle Cell Lymphoma: contributes to disease control when used in combination regimens.

Lenalidomide Orion may cause a range of adverse reactions.

Common Side Effects: - Fatigue: persistent tiredness affecting daily activities. - Neutropenia: reduced neutrophil count increasing infection risk. - Diarrhea: loose stools that may require supportive care. - Constipation: difficulty passing stool, often manageable with diet.

Serious or Rare Side Effects: - Venous thromboembolism: blood clots in deep veins or lungs. - Secondary primary malignancies: emergence of new cancers. - Severe skin reactions: Stevens‑Johnson syndrome or toxic epidermal necrolysis. - Liver enzyme elevation: significant increase in hepatic transaminases.

Before initiating therapy, clinicians should assess baseline health status and monitor ongoing safety. - Monitor blood counts: perform regular CBC to detect cytopenias. - Assess thromboembolic risk: consider prophylactic anticoagulation when indicated. - Contraindicated in pregnancy: teratogenic potential requires strict contraception. - Adjust for renal impairment: dose modifications may be necessary in reduced kidney function. - Store at room temperature: keep in the original container, protect from moisture and light.

Lenalidomide Orion can interact with several drug classes, requiring careful management.

Major Interactions (Avoid): - Strong CYP3A4 inducers (e.g., rifampin): may lower lenalidomide exposure. - Anticoagulants (e.g., warfarin): increased risk of thrombosis. - Live vaccines: heightened risk of infection due to immunosuppression.

Moderate Interactions (Monitor Closely): - CYP3A4 inhibitors (e.g., ketoconazole): may raise plasma levels. - NSAIDs: additive effect on bleeding risk. - Digoxin: potential increase in serum concentration.